Norris Perne & French LLP MI Sells 1,787 Shares of AbbVie Inc. $ABBV

Norris Perne & French LLP MI decreased its position in AbbVie Inc. (NYSE:ABBV) by 44.7% in the third quarter, Holdings Channel reports. The firm owned 2,210 shares of the company’s stock after selling 1,787 shares during the period. Norris Perne & French LLP MI’s holdings in AbbVie were worth $578,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Ranch Capital Advisors Inc. lifted its stake in shares of AbbVie by 37.0% during the 1st quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock worth $3,238,000 after purchasing an additional 4,017 shares during the last quarter. Capital Advisors Inc. OK boosted its position in AbbVie by 11.2% during the second quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company’s stock valued at $112,516,000 after purchasing an additional 45,132 shares in the last quarter. Danica Pension Livsforsikringsaktieselskab purchased a new position in AbbVie in the second quarter valued at about $23,557,000. Wedge Capital Management L L P NC grew its stake in AbbVie by 7.5% in the second quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company’s stock valued at $33,865,000 after purchasing an additional 9,380 shares during the last quarter. Finally, State Street Corp grew its stake in AbbVie by 1.7% in the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock valued at $20,784,646,000 after purchasing an additional 1,379,232 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

Shares of ABBV opened at $285.66 on Monday. The firm has a market capitalization of $504.70 billion, a PE ratio of 80.69, a price-to-earnings-growth ratio of 1.30 and a beta of 0.24. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $291.40. The company’s fifty day moving average price is $266.33 and its 200-day moving average price is $242.01.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The firm’s revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, research analysts anticipate that AbbVie Inc. will post 13.93 EPS for the current fiscal year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.4%. The ex-dividend date is Thursday, October 15th. AbbVie’s payout ratio is presently 195.48%.

Insider Buying and Selling at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Analyst Upgrades and Downgrades

ABBV has been the subject of a number of recent research reports. Bank of America reiterated a “buy” rating on shares of AbbVie in a report on Tuesday, September 8th. Rothschild & Co Redburn raised their price target on shares of AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. BNP Paribas Exane lifted their price objective on shares of AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 11th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $280.00 price objective on shares of AbbVie in a research report on Tuesday, October 13th. Finally, UBS Group boosted their price objective on shares of AbbVie from $260.00 to $275.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 6th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus target price of $279.86.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The U.S. FDA approved a subcutaneous induction regimen for SKYRIZI in adults with moderately to severely active Crohn’s disease. The on-body injector provides a more convenient administration option throughout treatment, while Phase 3 data showed superior clinical remission and endoscopic response versus placebo with no new safety risks. The approval could strengthen SKYRIZI’s commercial position and support AbbVie’s post-Humira growth strategy. FDA approves subcutaneous SKYRIZI induction for Crohn’s disease
• Positive Sentiment: AbbVie’s dividend remains a key defensive attraction. Analysts and financial commentators point to the company’s ability to maintain shareholder payouts despite Humira’s patent loss, supported by growth from SKYRIZI, RINVOQ and other newer products. AbbVie’s dividend after Humira’s patent cliff
• Neutral Sentiment: AbbVie’s Phase 3 INTREPID trial for lutikizumab in hidradenitis suppurativa met its primary endpoint and eight ranked secondary endpoints, including reduced pain and fewer flares. However, reported efficacy was viewed by some analysts as underwhelming relative to competing treatments, leaving the drug’s eventual commercial opportunity uncertain. AbbVie reports Phase 3 INTREPID results for lutikizumab
• Negative Sentiment: Investors are approaching next week’s earnings report cautiously. Erste Group lowered its 2026 EPS estimate to $13.90 from $14.00, slightly below the roughly $13.94 consensus, while a Zacks preview said AbbVie lacks the usual indicators for a likely earnings beat. With the shares trading near their 52-week high and at a premium valuation, results and guidance may need to be strong to sustain momentum. AbbVie earnings preview

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.